Endonovo Therapeutics (OTCMKTS:ENDV) Reaches Distribution Agreement with Academy Medical | News Direct

Endonovo Therapeutics (OTCMKTS:ENDV) Reaches Distribution Agreement with Academy Medical

News release by TopNewsGuide - Market News & Commentary

facebook icon linkedin icon twitter icon pinterest icon email icon Naples, FL | March 09, 2023 05:00 AM Eastern Standard Time


There are a number of interesting companies which may well be worth the attention of investors at this point in time and one of those could well be Endonovo Therapeutics (OTCMKTS:ENDV). Before getting into some of the key new developments with regard to Endonovo it could be a better idea to have a closer look at the nature and structure of its operations.

The company is currently divided into two main divisions. The first one is its legacy business, which is involved in the development of noninvasive wearable 'Electroceuticals' therapeutic devices meant for pain relief, wounds, and wellness. Most of the products manufactured by Endonovo under the legacy business are sold under the SofPulse brand. The other business division is the Build Up Strategy which is involved in the acquisition of complementary specialty service providers involved in the construction industry.

The company was in the news cycle earlier on in the week on March 6 after it announced that it had signed a Service-Disabled Veteran-Owned Small Business (SDVOSB) Government Reseller Agreement with the West Palm Beach-based firm Academy Material Inc.

As per the provisions of the agreement between the two parties, the agreement would involve the distribution of SofPulse branded medical devices so as to make sure that those devices are available to the Department of Defence and Veterans Health Administration contracts. The new contract is a vital one since it would allow Endonovo to team up with Academy Material for bringing the highest class of surgical and medical supplies, in addition to telehealth services to veterans and the military.

In this context, it is perhaps also necessary to keep in mind that the Pulse Electro Magnetic Frequency (PEMF) electromagnetic devices sold under the SofPulse brand had been cleared by the United States Food and Drug Administration.

The devices are also clinically proven with regard to the successful reduction of edema and postoperative pain. At this point in time, the company’s Medical Device Division is working on the commercialization of the SofPulse telehealth and medical device initiatives. The latest agreement is also going to help in further expanding the scale of distribution of SofPulse branded products.

The company has been working diligently for the sole purpose of expanding the distribution and presence of its SofPulse brand of products. In this regard, it should be noted that back on January 26 earlier this year, the company announced that it had signed a stocking distributor agreement of a non-exclusive nature with the firm Pulse Therapeutic Technology Inc.

Pulse would be responsible for purchasing its SofPulse products and then distributing those in Costa Rica and Mexico. As a distributor, Pulse seemed to have gauged the potential of the products and had purchased as much as $100,000 of those products for the purpose of marketing and testing in Costa Rica and Mexico.

The testing proved to be successful, and eventually, Pulse placed a purchase order to the tune of as much as $350,000. Endonovo noted at the time that it was going to work closely with the distributor through SofPulse Inc, its subsidiary.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TopNewsGuide 'TNG' (Owned by RazorPitch Inc) is responsible for the production and distribution of this content. TNG is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. TNG authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. TNG has not been compensated to produce and syndicate this content. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website http://topnewsguide.com


Contact Details


Mark McKelvie


+1 585-301-7700




Company Website




Endonovo Therapeutics (OTCMKTS:ENDV)ENDVENDV StockEndonovo TherapeuticsEndonovo Therapeutics StockEndonovo Therapeutics (OTC:ENDV)Academy Medical